Profound Medical prices 5.14M shares at $7.00 in registered direct offering

Profound Medical (PROF) announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering and a planned subsequent private placement in Canada of up to 571,428 common shares at a purchase price of $7.00 per share for aggregate gross proceeds of up to $40M. The registered direct offering was structured as a straightforward equity investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders. This portion of the offering is expected to close on or about Monday, December 22, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds to the Company from the offering are expected to be approximately $36M, before deducting placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for expansion of its sales and marketing, working capital, research and development, strategic transactions and general corporate purposes. Konik Capital Partners, a division of T.R. Winston and Company, is acting as the exclusive placement agent for this offering.